These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15876908)

  • 21. [Study of dissociative disorders and depersonalization in a sample of young adult French population].
    Moyano O; Claudon P; Colin V; Svatos J; Thiébaut E
    Encephale; 2001; 27(6):559-69. PubMed ID: 11865563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
    Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
    JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depersonalization and derealization in self-report and clinical interview: The spectrum of borderline personality disorder, dissociative disorders, and healthy controls.
    Sar V; Alioğlu F; Akyuz G
    J Trauma Dissociation; 2017; 18(4):490-506. PubMed ID: 27681414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naltrexone treatment of adolescent alcoholics: an open-label pilot study.
    Deas D; May MP; Randall C; Johnson N; Anton R
    J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):723-8. PubMed ID: 16262589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naltrexone as a treatment of self-injurious behavior--a case report.
    Griengl H; Sendera A; Dantendorfer K
    Acta Psychiatr Scand; 2001 Mar; 103(3):234-6. PubMed ID: 11240582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of naltrexone in the treatment of chronic refractory itching in burn patients: preliminary report of an open trial.
    Jung SI; Seo CH; Jang K; Ham BJ; Choi IG; Kim JH; Lee BC
    J Burn Care Res; 2009; 30(2):257-60; discussion 261. PubMed ID: 19165115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naltrexone as a treatment for repetitive self-injurious behaviour:an open-label trial.
    Roth AS; Ostroff RB; Hoffman RE
    J Clin Psychiatry; 1996 Jun; 57(6):233-7. PubMed ID: 8666558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive functioning in depersonalization disorder.
    Guralnik O; Giesbrecht T; Knutelska M; Sirroff B; Simeon D
    J Nerv Ment Dis; 2007 Dec; 195(12):983-8. PubMed ID: 18091191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basal norepinephrine in depersonalization disorder.
    Simeon D; Guralnik O; Knutelska M; Yehuda R; Schmeidler J
    Psychiatry Res; 2003 Nov; 121(1):93-7. PubMed ID: 14572626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.
    Grant JE; Kim SW; Odlaug BL
    Biol Psychiatry; 2009 Apr; 65(7):600-6. PubMed ID: 19217077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression.
    Adamson SJ; Sellman JD; Foulds JA; Frampton CM; Deering D; Dunn A; Berks J; Nixon L; Cape G
    J Clin Psychopharmacol; 2015 Apr; 35(2):143-9. PubMed ID: 25679122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
    Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
    Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial.
    Heinälä P; Alho H; Kiianmaa K; Lönnqvist J; Kuoppasalmi K; Sinclair JD
    J Clin Psychopharmacol; 2001 Jun; 21(3):287-92. PubMed ID: 11386491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of personality disorders on alcohol-use outcomes in a pharmacotherapy trial for alcohol dependence and comorbid Axis I disorders.
    Ralevski E; Ball S; Nich C; Limoncelli D; Petrakis I
    Am J Addict; 2007; 16(6):443-9. PubMed ID: 18058408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness.
    Maxwell S; Shinderman MS
    J Addict Dis; 2000; 19(3):61-9. PubMed ID: 11076120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
    Collins ED; Kleber HD; Whittington RA; Heitler NE
    JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low Dose Naltrexone in the Treatment of Fibromyalgia.
    Metyas S; Chen CL; Yeter K; Solyman J; Arkfeld DG
    Curr Rheumatol Rev; 2018; 14(2):177-180. PubMed ID: 28325149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
    Younger J; Noor N; McCue R; Mackey S
    Arthritis Rheum; 2013 Feb; 65(2):529-38. PubMed ID: 23359310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients.
    Sturn KM; Collin M
    Int J Pharm Compd; 2016; 20(3):197-201. PubMed ID: 28333660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.